Know Cancer

forgot password

A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy

Phase 2
18 Years
Open (Enrolling)
Prostate Cancer

Thank you

Trial Information

A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy

This study is a multicenter Phase 2, randomized, double-blind, efficacy and safety study of
enzalutamide (160 mg/day) vs. bicalutamide (50 mg/day) in patients with recurrent prostate
cancer who have serologic and/or radiographic disease progression despite primary androgen
deprivation therapy.

Throughout the study, safety and tolerability will be assessed by the recording of adverse
events, monitoring of vital signs, physical examinations, and safety laboratory evaluations.

Inclusion Criteria:

- Males age 18 or older;

- Histologically or cytologically confirmed adenocarcinoma of the prostate;

- Ongoing androgen deprivation therapy

- Serum testosterone level ≤ 50 ng/dL (1.73 nmol/L) at the Screening visit;

- Progressive disease at study entry defined by PSA progression and/or radiographic
progression that occurred while the patient was on primary androgen deprivation

- Asymptomatic or mildly symptomatic from prostate cancer;

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;

- Estimated life expectancy of ≥ 12 months;

- Able to swallow the study drug and comply with study requirements.

Exclusion Criteria:

- Severe concurrent disease, infection, or co-morbidity;

- Known or suspected brain metastasis or active leptomeningeal disease;

- History of another invasive malignancy within the previous 5 years other than
curatively treated non-melanomatous skin cancer and American Joint Committee on
Cancer (AJCC) Stage 0 or Stage 1 cancers that have a remote probability of

- Absolute neutrophil count < 1,500/µL, or platelet count < 100,000/µL, or hemoglobin <
9 g/dL at the Screening visit;

- Total bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >
2.5 times the upper limit of normal (ULN) at the Screening visit;

- Creatinine > 2 mg/dL at the Screening visit;

- Albumin < 3.0 g/dL at the Screening visit;

- History of seizure or any condition that may predispose to seizure;

- Clinically significant cardiovascular disease;

- Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic
ulcer disease within last 3 months);

- Major surgery within 4 weeks of enrollment;

- Use of opiate analgesics for pain from prostate cancer within 4 weeks of enrollment;

- Radiation therapy for treatment of the primary tumor within 3 weeks of enrollment;

- Prior ketoconazole, abiraterone, or cytotoxic chemotherapy for prostate cancer;

- Use of antiandrogens within 4 weeks prior to enrollment;

- Prior disease progression, as assessed by the Investigator, while receiving

- Participation in a previous clinical trial of enzalutamide or an investigational
agent that inhibits the androgen receptor or androgen synthesis (patients who
received placebo are acceptable);

- Use of an investigational agent within 4 weeks of enrollment;

- Use of herbal products that may have hormonal anti-prostate cancer activity and/or
are known to decrease PSA levels (e.g., saw palmetto) or systemic corticosteroids for
prostate cancer within 4 weeks of enrollment;

- Any condition or reason that, in the opinion of the Investigator, interferes with the
ability of the patient to participate in the trial, which places the patient at undue
risk, or complicates the interpretation of safety data.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Outcome Measure:

Progression Free Survival (PFS)

Outcome Time Frame:

24 months

Safety Issue:


Principal Investigator

Fong Wang, MD, PhD

Investigator Role:

Study Director

Investigator Affiliation:

Medivation, Inc.


United States: Food and Drug Administration

Study ID:




Start Date:

July 2012

Completion Date:

July 2014

Related Keywords:

  • Prostate Cancer
  • prostate cancer
  • enzalutamide
  • MDV3100
  • Prostatic Neoplasms



Bettendorf, Iowa  52722
Alexandria, Minnesota  56308
Birmingham, Alabama  35294
Phoenix, Arizona  85012
Fountain Valley, California  92708
Miami, Florida  33176
Columbia, Missouri  65203
Albany, New York  12208
Cleveland, Ohio  44195
Philadelphia, Pennsylvania  19104
Nashville, Tennessee  37203-1632
Austin, Texas  78705
Seattle, Washington  98195
Flint, Michigan  48532
McLean, Virginia  22101
Omaha, Nebraska  68114
Hackensack, New Jersey  07601
Metairie, Louisiana  70006
Denver, Colorado  
Baltimore, Maryland  21287
Charlotte, North Carolina  
Eugene, Oregon  
Milwaukee, Wisconsin  
Indianapolis, Indiana  
Charleston, South Carolina  
Washington, District of Columbia  
Salt Lake City, Utah  84112